Hookipa Pharma (NASDAQ:HOOK) Given “Neutral” Rating at HC Wainwright

Posted by ABMN Staff on Jan 12th, 2025

Hookipa Pharma (NASDAQ:HOOK – Get Free Report)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a note issued to investors on Friday, MarketBeat.com reports.

HOOK has been the topic of several other research reports. Royal Bank of Canada cut shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $48.00 to $2.00 in a research report on Friday, December 20th. JMP Securities reduced their price target on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, November 21st.

Check Out Our Latest Research Report on Hookipa Pharma

Hookipa Pharma Trading Up 15.6 %

NASDAQ:HOOK opened at $2.15 on Friday. The stock has a 50-day moving average price of $2.48 and a 200 day moving average price of $4.10. The stock has a market capitalization of $25.92 million, a P/E ratio of -0.58 and a beta of 0.71. Hookipa Pharma has a 12-month low of $1.75 and a 12-month high of $10.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HOOK. Renaissance Technologies LLC increased its position in Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after purchasing an additional 83,800 shares during the last quarter. Ikarian Capital LLC bought a new position in Hookipa Pharma during the third quarter valued at $228,000. Finally, Acadian Asset Management LLC grew its stake in shares of Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after buying an additional 108,844 shares in the last quarter. 63.88% of the stock is currently owned by institutional investors.

Hookipa Pharma Company Profile

(Get Free Report)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.